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ABSTRACT
Pulmonary dysfunction is a significant complication following allogeneic hematopoietic stem cell transplan-
tation (HSCT), and is associated with significant morbidity and mortality. Effective antimicrobial prophylaxis
and treatment strategies have increased the incidence of noninfectious lung injury, which can occur in the early
posttransplant period or in the months and years that follow. Late-onset noninfectious pulmonary complica-
tions are frequently encountered, but diagnostic criteria and terminology for these disorders can be confusing
and therapeutic approaches are suboptimal. As a consequence, inaccurate diagnosis of these conditions may
hamper the appropriate data collection, enrollment into clinical trials, and appropriate patient care. The
purpose of this review is to clarify the pathogenesis and diagnostic criteria of representative conditions, such
as bronchiolitis obliterans syndrome and bronchiolitis obliterans organizing pneumonia, and to discuss the
appropriate diagnostic strategies and treatment options.
© 2007 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic bone marrow transplan-
ation (allo-HSCT) is a curative treatment option for
variety of malignant and nonmalignant disorders.
owever, a number of complications associated with
he occurrence of either acute or chronic graft versus
ost disease (aGVHD, cGVHD) have limited the util-
ty of this procedure. In particular, pulmonary com-
lications occur in 25%-50% of allo-HSCT recipi-
nts, and can account for approximately 50% of
ransplant related deaths [1-6]. In nearly 50% of cases,
o infectious organisms are identiﬁed in the lungs of
ffected individuals. Both an acute and a subacute pattern of lung injury have been recognized in this
ontext (Figure 1). Noninfectious, acute lung injury
as been deﬁned as idiopathic pneumonia syndrome
IPS). IPS occurs with in the ﬁrst 120 days after
SCT and typically has a rapidly progressing fulmi-
ant course resulting in death in 60% to 80% of
atients. By contrast, subacute lung injury is associ-
ted with a later onset, typically6 months posttrans-
lant, and the clinical course tends to be more insid-
ous and protracted (Figure 1). This review will focus
n 2 common subacute or late-onset pulmonary com-
lications, namely bronchiolitis obliterans syndrome
BOS), and bronchiolitis obliterans with organizing
neumonia (BOOP).
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S. Yoshihara et al.750OS
“Bronchiolitis obliterans” describes a histologic
attern of small airway inﬂammation that includes
brogenic deposition in small airways or bronchioles.
ronchioles consist of terminal bronchioles and respi-
atory bronchioles, and serve as the bridge between
onducting airways and alveoli. BO is synonymous
ith the term “constrictive bronchiolitis,” and is man-
fested clinically by the presence of airﬂow obstruction
nd recognized histologically by submucosal bron-
hiolar ﬁbrosis, along with luminal narrowing and
bliteration. BOS is a clinical term deﬁned by pulmo-
ary function changes rather than histology [7-10].
OS is deﬁned as an irreversible decline in forced
xpiratory volume in 1 second (FEV1) of at least 20%
rom baseline, and is graded using the International
ociety for Heart and Lung Transplantation (ISHLT)
riteria [11]. Although BO and BOS may include dif-
erent patient cohorts, indicated by the fact that some
atients with positive histologic ﬁndings of BO do not
ave pulmonary function changes seen in BOS, these
entities are believed to greatly overlap, and the terms
end to be used interchangeably [9,11].
ATHOGENESIS
The pathogenesis of BOS after HSCT has not
een well deﬁned. However, the heterogeneous his-
opathologic ﬁndings and clinical course suggest that
he development of BOS is a multifactorial process
nvolving both alloimmunologic and nonalloimmuno-
ogic reactions. Because the occurrence of BOS has
een closely associated with cGVHD, it has been
ypothesized that BOS is mediated, at least in part, by
lloimmunologic injury to host bronchiolar epithelial
ells [12]. Unlike IPS, elevations of pro-inﬂammatory
ytokine levels within the serum and broncho-alveolar
avage (BAL) compartment of affected subjects have
ot been well documented in humans or animal mod-
ls [13-21]. Murine models have suggested, however,
igure 1. Schematic diagram of the time of occurrence of IPS,
OOP, and BOS.hat lymphocytes and associated chemokines and cyto- Hines, including tumor necrosis factor alpha (TNF),
ay be important contributors to the development of
he chronic inﬂammatory process that characterizes
OS after lung transplantation [13,14,22,23]. The
athogenesis of disease is believed to primarily involve
he interplay between immune effector cells (mono-
ytes, lymphocytes, neutrophils) that have been re-
ruited to the lung and cells resident to the pulmonary
ascular endothelium and interstitium. This complex
rocess results in the loss of type I pulmonary epithe-
ial cells, proliferation of type II cells, the recruitment
nd proliferation of endothelial cells, and the deposi-
ion of the extracellular matrix. In response to this
attern of injury, cytokines released from these effec-
or cells and lung cells (macrophages, alveolar epithe-
ial, and vascular endothelial cells) can stimulate ﬁbro-
last proliferation and increase the synthesis of
ollagen and extracellular matrix proteins. Ultimately,
his leads to enhanced deposition of collagen and
ranulation tissue in and around bronchial structures,
nd eventually complete obliteration of small airways
Figure 2) [12].
Clinical data suggest that nonalloimmunologic in-
ammatory conditions such as viral infections, recur-
ent aspiration, and conditioning chemoradiotherapy
ay also play a role in the pathogenesis of BOS after
SCT. A recent report indicated that respiratory
ract infections with some community respiratory vi-
uses (parainﬂuenza virus and respiratory syncytial vi-
us) were associated with late airﬂow decline [15].
OS after autologous transplantation and decreased
isk of BOS after reduced intensity conditioning sup-
ort a contribution to tissue damage from chemora-
iotherapy that is part of HSCT conditioning regi-
ens [16,17], as has been observed with IPS [18].
NCIDENCE AND RISK FACTORS
Because of the lack of deﬁned diagnostic criteria,
he reported incidence of BOS following allo-HSCT
aries widely from 1.7% to 26% [8,19-21,24]. As
oted above, the development of BOS in both pedi-
tric and adult populations is closely associated with
he occurrence of cGVHD. Other potential risk fac-
ors that have been identiﬁed include the use of meth-
trexate for aGVH prophylaxis [8], decreased serum
gG levels [19], the prior occurrence of acute GVHD
25], older recipient age, older donor age [26], lower
retransplant FEV1/forced vital capacity (FVC) ratio,
espiratory viral infections within the ﬁrst 100 days
osttransplant [20], busulfan-based conditioning
egimen, peripheral blood stem cell transplantation,
emale donor to male recipient, a prior episode of
nterstitial pneumonitis [24], and the intensity of
SCT conditioning [17].
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Pulmonary Complications following Allogeneic HSCT 751LINICAL PRESENTATION
The onset of BOS varies from 3 months to 10
ears, with a median onset approximately 1 year post-
SCT [10,21,24,27,28]. Common symptoms include
rogressive dyspnea, nonproductive cough, and
heezing. Unlike BOOP, fever is usually absent in
OS. Many patients remain asymptomatic for long
eriods, despite having evidence of moderate to severe
irway obstruction on pulmonary function tests. In
his context, and because 33% of patients with
GVHD develop signs of airﬂow obstruction [20],
lose observation should be a part of the follow-up
lans in these patients.
IAGNOSIS
ulmonary Function Testing (PFT)
Airﬂow obstruction is the hallmark of BOS. A
ecrease in forced expiratory volume in 1 second
FEV1) and diminished FEV1/FVC ratio are ob-
erved. Total lung capacity is not usually affected
Table 1). Lung diffusion capacity for carbon mon-
xide (DLCO) is often decreased; however, this is a
onspeciﬁc ﬁnding that may be seen in many pa-
ients following HSCT irrespective of airﬂow ob-
truction [29].
For patients undergoing allogeneic lung trans-
lantation, ISHLT diagnostic criteria for BOS in-
lude a20% decline in FEV1 values when compared
ith the postoperative baseline [30]. Recently, the
ntroduction of forced expiratory ﬂow rates (FEF25-
Figure 2. Histology of BO. Characterized by concentric obs5) has been added to these diagnostic criteria [31]. Inomparison to FEV1, the FEF25-75 may be a more
ensitive indicator of early airﬂow obstruction in BOS
ollowing allogeneic lung transplant [32].
In several studies, airﬂow obstruction has been
eﬁned as a decrease of the FEV1/FVC ratio to 0.7
nd FEV1 to 80% of the predicted value [21,27].
hien et al. [20] recently proposed new criteria, in
hich patients were deﬁned as having airﬂow obstruc-
ion if the annualized rate of predicted FEV1 decline
n of the small airways and relative sparing of alveolar space.
able 1. Comparison of Clinical Presentations of BOS and BOOP
BOS BOOP
ymptom Progressive dyspnea Fever
Non productive cough Nonproductive cough
Wheezing Dyspnea (usually
mild)
hysical exam. Wheezing Rales
ab data Non specific Elevated level of CRP
Increased neutrophil
FT Obstructive lung disease Restrictive lung
disease
FEV1/FVC Decreased Normal
TLC Normal Decreased
DLCO Decreased Decreased
adiology
CT scan Air trapping (expiration
phase)
Consolidation
Mosaic perfusion Ground glass opacity
Bronchiectasis Nodules
Bronchial wall thickening
Centrilobular nodules
FT indicates pulmonary function test; BOS, bronchiolitis obliter-
ans syndrome; BOOP, bronchiolitis obliterans organizing pneu-
moria.
w
t
c
a
a
y
[
d
m
R
B
T
(
h
3
p
e
m
a
B
B
u
p
r
A
d
t
l
w
t
c
c
t
d
b
o
r
o
t
i
H
u
ﬁ
r
d
T
a
s
t
a
t
k
r
S. Yoshihara et al.752as 5% per year and the lowest documented post-
ransplant FEV1/FVC ratio was 0.8. Using these
riteria, the investigators showed that development of
irﬂow decline by day 100 posttransplant was associ-
ted with an increased risk for airﬂow obstruction at 1
ear, but was not with an increase in mortality risk
33]. By contrast, patients with the fastest rate of
ecline between day 100 and 1 year had the highest
ortality risk.
adiographic Findings
Chest X-rays are often normal in patients with
OS, although hyperinﬂation has been described [27].
he role of high-resolution computed tomography
HRCT) or thin-section CT in the diagnosis of BOS
as been explored in lung transplant recipients [26,34-
6]. Characteristic ﬁndings of BOS include air trap-
ing, mosaic perfusion, bronchial dilatation (bronchi-
ctasis), and bronchial wall thickening. Air trapping
ay be demonstrated on HRCT during expiration,
nd had the highest sensitivity for the development of
OS in lung transplant recipients (Figure 3) [34].
RONCHOSCOPY AND LUNG BIOPSY
Bronchoscopy with BAL in patients with BOS is
sually nonspeciﬁc, showing neutrophilic and/or lym-
hocytic inﬂammation [37], but is essential to help
ule out infectious causes of pulmonary dysfunction.
lthough lung biopsy is the only way to deﬁnitively
iagnose BO, it is infrequently performed in the set-Figure 3. CT scan of BOS. Mosaic pattern of air trings of BOS after HSCT. Although transbronchial
ung biopsies (TBLB) can be routinely performed
ith minimal risk of hemorrhage and pneumothorax,
he sensitivity of such testing is suboptimal. In 1 re-
ent report, only 15% to 40% of patients with BOS
ould be provided with histologic conﬁrmation with
his procedure [38]. The low sensitivity of the proce-
ure is likely related to the patchy nature of BO and
ecause of the small quantity of bronchiolar material
btained. Surgical lung biopsy by video-assisted tho-
ocoscopic surgery (VATS) is useful; however, it is
ften avoided because of the surgical risks present in
his population.
Because histologic conﬁrmation can be obtained
n only a limited number of patients, BOS following
SCT is usually a clinical diagnosis that is made based
pon clinical symptoms, PFT results, and radiologic
ndings. Respiratory infections and BOOP should be
uled out with imaging and other appropriate proce-
ures.
REATMENT OF BOS
Based on the premise that BOS results from an
lloimmunologic reaction, augmentation of immuno-
uppression has been widely used as the initial line of
reatment. The use of corticosteroids with prednisone
t 1-1.5 mg/kg/day over 4-6 weeks [9] or pulsed cor-
icosteroid dosing with methylprednisolone (10 mg/
g/day  3 days every month up to 6 cycles) has been
eported [39]. A recent report suggested that inhaledapping is clearly shown in expiratory phase.
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Pulmonary Complications following Allogeneic HSCT 753yclosporine may be effective both in the prevention
nd treatment of BOS after lung transplantation
40,41], but this strategy has not been investigated in
SCT recipients. The role of azithromycin has also
een explored in the setting of lung transplantation
42,43]. Recently, the efﬁcacy of azithromycin (500
g every day for 3days, followed by 250 mg 3 times a
eek for 12 weeks) has been reported in the treatment
f a small number of patients with BOS after HSCT
44]. Azithromycin has been shown to have aniti-
nﬂammatory effects, particularly with respect to IL-8
nd airway neutrophilia, and these properties may
ontribute to beneﬁcial effects observed in BOS [45].
iven the potential role of inﬂammatory cytokines,
he use of TNF neutralizing agents has also been
eported, and may represent a novel therapy for the
anagement of BOS. Yanik et al. [46] reported the
otential efﬁcacy of etanercept, human TNF neu-
ralizing agent, in the treatment of IPS and have found
hat this molecule may be useful for subacute lung
njury as well [47]. Larger prospective trials in each
etting are ongoing. Fullmer et al. [48] reported a case
f BOS following HSCT in a pediatric patient that
as successfully treated with inﬂiximab, a monoclonal
ntibody for human TNF. Other interventions in-
luding the long-term administration of intravenous
mmunoglobulin has failed to show the effect on pre-
enting the development of BOS [49]. Extracorporeal
hotochemotherapy (ECP), which has been shown to
e a promising treatment for cGVHD [50,51], has
een used with some success for BOS following lung
ransplantation [52]. However, only a few case reports
re available that examine the effectiveness of this
herapy for BOS after HSCT [53,54]. Because of the
oor response to traditional therapies, lung transplan-
ation has been increasingly reported as a possible
herapeutic option for end-stage BOS after HSCT
55-60].
ROGNOSIS
Despite treatment with augmented immunosup-
ression, the prognosis for patients with BOS remains
oor. Improvement of lung function once signiﬁcant
mpairment has occurred can be obtained in only a
inority of the patients. Mortality remains high, vary-
ng from 14% to 100% (mean 61%) [61]. In the
ajority of cases, death is attributed to progressive
espiratory failure and opportunistic pulmonary infec-
ions. Clark et al. [27] reported that a 3-year mortality
ate of 65% in the patients with BOS accompanying
GVHD. Rapid decline in FEV1 [27,33], resistance to
rst-line therapy [21], earlier onset (earlier than 6
onths or 200 days) [17,21] are all factors reported to
e associated with a worse prognosis. tOOP
BOOP is a disorder involving bronchioles, alveo-
ar ducts, and alveoli, the lumen of which become
lled with buds of granulation tissue consisting of
broblasts and an associated matrix of loose connec-
ive tissue. The bronchiolitis in BOOP is of the pro-
iferative type, and generally includes mild inﬂamma-
ion of the bronchiolar walls. In contrast to BO, there
s no prominent bronchiolar wall ﬁbrosis or bronchio-
ar distortion [62]. The intraluminal lesions and con-
equent organizing pneumonia are the most signiﬁ-
ant histopathologic ﬁndings in BOOP. Recently,
diopathic BOOP has been termed cryptogenic orga-
izing pneumonia (COP) to avoid confusion with the
O nomenclature [63].
ATHOGENESIS
Although the pathogenesis of BOOP following
SCT is poorly understood, involvement of an allo-
mmunologic reaction has been again been consid-
red. In animal studies, BOOP develops following
nfection with reovirus, and a signiﬁcant role for
cells and Th1-derived cytokines, including inter-
eron-, was implicated in the development of disease
64]. A case reported following syngeneic bone mar-
ow transplantation suggests that BOOP is not always
he result of an allogeneic immune response [65]. In
ther non-HSCT settings BOOP has been seen in
ssociation with infection, drugs, radiation therapy,
nd a number of connective tissue disorders [62].
NCIDENCE AND RISK FACTORS
Patients with BOOP following HSCT have been
escribed in several reports [62,65-73]. Freudenberger
t al. [74] recently reported a case-control study of
istologic BOOP. Of 5340 patients who received allo-
SCT, 49 cases (0.9%) of histologic BOOP were
dentiﬁed. An association between aGVHD and
GVHD and the subsequent development of BOOP
as noted. Patients with BOOP were more likely to
ave acute cutaneous GVHD and cGVHD involving
he gut and oral cavity. In other reports, 3 of 179
1.6%) patients receiving matched sibling donor
SCT [72] and 4 of 39 (10.3%) patients who received
nrelated donor HSCT developed BOOP [75].
LINICAL PRESENTATION
The onset of BOOP has been reported to vary
rom 5 to 2800 days posttransplant, with a median
ccurrence by day 108 post-HSCT [74] Following
SCT, BOOP has a similar clinical presentation tohat seen with idiopathic BOOP (a.k.a. COP). Fever,
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S. Yoshihara et al.754onproductive cough, and dyspnea are all typically
oted. On physical examination, rales are common,
ut wheezing is generally absent. Elevations in serum
evels of C-reactive protein have been seen in con-
unction with a moderate leukocytosis and neutro-
hilia.
IAGNOSIS
FT
PFTs typically reveal a mild to moderate restric-
ive defect, the degree of which depends on the extent
f the pulmonary inﬂammation. DLCO is commonly
ecreased, and in contrast with BOS, airﬂow obstruc-
ion is usually absent.
adiology
The radiologic ﬁndings in idiopathic BOOP in-
lude diffuse, “ﬂuffy” consolidations, ground glass
pacity, and nodules (Figure 4). Consolidation is often
igratory [76,77]. Lee et al. [78] reported the CT
ndings in 43 patients with biopsy-proven idiopathic
OOP. The most common pattern was consolidation,
resent alone or as part of a mixed pattern in 79% of
ases. The consolidation had a predominantly sub-
leural and/or peribronchovascular distribution.
round-glass opacity and nodules were seen in 60%
nd 30%, respectively. Of note, BOOP in immuno-
ompromised patients (following HSCT, with leuke-
ia, or myelodysplastic syndrome) showed different
adiographic patterns from that in immunocompetent
atients. Less areas of consolidation (45% versus
1%), greater ground-glass involvement (73% versus
6%) and more frequent pulmonary nodules (55%cFigure 4. CT scan of BOOP. Consolidation/nodules are shown.ersus 22%) are seen in this group. Dodd et al. [79]
ecently reported the HRCT ﬁndings of 4 patients
ith BOOP following HSCT. All patients showed
onsolidation and signiﬁcant ground-glass opaciﬁca-
ions.
ronchoscopy and Lung Biopsy
Bronchoscopy and BAL are useful in ruling out
ulmonary infection and establishing the diagnosis of
OOP (Figure 5). BAL ﬂuid reveals lymphocytosis,
ith a decreased CD4/CD8 ratio. Despite the useful-
ess of BAL, histologic conﬁrmation is still believed to
e necessary for a diagnosis of BOOP. Unlike BO,
OOP usually can be sufﬁciently diagnosed with
BLB by demonstrating organizing pneumonia.
ATS is required in the cases with atypical features
r in whom the diagnosis cannot be made with
BLB [80].
REATMENT AND PROGNOSIS
Although there is no standardized treatment pro-
ocol for BOOP after HSCT, corticosteroid is the
ainstay of therapy. In the treatment of idiopathic
OOP, prolonged treatment (prednisone 1 mg/kg for
-3 months, 40 mg for 3 months, followed by 10-20
g for a total of 1 year) was proposed to avoid relapses
81]. The rate of relapse in idiopathic BOOP varies
rom 9% to 58%, although relapses may not neces-
arily affect long-term outcome [80]. Based on this
act, the use of lower corticosteroid dosages with a
horter duration of treatment (prednisone 0.75 mg/kg
or 4 weeks, 0.5 mg/kg for 4 weeks, 10 mg for 6 weeks,
mg for 6 weeks) has been proposed [82]. The role of
acrolides has also been explored also in the treat-
ent in BOOP [73].
Freudenberger et al. [74] reported that BOOP
fter HSCT resolved in 57% and remained stable in
1% of cases. BOOP progressed in 22% of patients
espite corticosteroids, with the majority of these pa-
ients (16% of total) dying from respiratory failure.
lthough the overall prognosis of idiopathic BOOP is
ood, with mortality rates 5% to 15%, the prognosis
f BOOP after HSCT still remains to be deﬁned, and
s potentially lower [69,75].
THER COMPLICATIONS
Pulmonary veno-occlusive disease (PVOD) is a
are complication observed following both auto- and
llo-HSCT that results in pulmonary hypertension
83-88]. The pathologic hallmark of PVOD is the
xtensive and diffuse occlusion of pulmonary veins by
brous tissue [89]. In addition to HSCT recipients,
VOD has been reported in patients who received
hemotherapy [90] and in patients with an associated
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Pulmonary Complications following Allogeneic HSCT 755iral illness [91]. Autoimmune destruction of pulmo-
ary venules has not been commonly observed in
hose patients, and only a minority of patients with
VOD have associated autoimmune disorders [92].
hese ﬁndings suggest that PVOD after HSCT is a
esult of tissue injury from HSCT conditioning
nd/or infection. The onset of PVOD varies from a
onth to a year after HSCT. Most patients with
VOD present with nonspeciﬁc complaints such as
yspnea on exertion and fatigue. The physical exam-
nation and radiologic ﬁndings are consistent with
ulmonary hypertension. Right heart catheterization
hows elevated pulmonary artery pressure with nor-
al pulmonary artery wedge pressure. The triad of
evere pulmonary hypertension, radiographic evi-
ence of pulmonary edema, and a normal pulmonary
Figure 5. Histology of BOOP. Alveolartery occlusion pressure is thought to be diagnostic of PVOD. However, many patients with PVOD do not
ave this triad. Surgical lung biopsy is the only way for
deﬁnitive diagnosis, and thus should be considered
o conﬁrm the clinical suspicion of PVOD [89]. Most
eported cases of PVOD after HSCT were treated
ith high-dose corticosteroids, with minimal effec-
iveness, and the prognosis of PVOD remains poor.
Pulmonary cytolytic thrombi (PCT) is a recently
ecognized rare noninfectious pulmonary complica-
ion seen almost exclusively in pediatric patients post
llo-HSCT [93-97]. PCT appears as pulmonary
hrombi in small to medium distal pulmonary vessels,
onsisting predominantly of monocytes of both donor
nd recipient origin, and associated with hemorrhagic
ulmonary infarction [94,97]. The onset ranges be-
ween 8 and 343 days (median 72 days) after HSCT.
is occupied by organizing pneumonia.CT presents with fever, cough, chest pain, respira-
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S. Yoshihara et al.756ory distress. Chest CT scans may reveal multiple
mall peripheral or subpleural nodules and opacities of
arying size. The majority of cases had active aGVHD
r cGVHD. Woodard et al. [93] reported that 9 of 13
atients with PCT were alive with a median follow-up
f 1.5 years. Several patients showed clinical improve-
ent and radiologic resolution of their pulmonary
odules after immunosuppressive therapy was admin-
stered.
As noted earlier, acute noninfectious interstitial
neumonitis (IP) occurring within 120 days after
SCT is termed IPS. In the majority of cases, affected
atients also exhibit signs of aGVHD. In contrast, it
as been reported that patients develop progressive IP
uch later (11 months to 8 years) after HSCT in
ssociation with severe cGVHD, especially scleroder-
atous skin GVHD [75,98,99]. This late onset pro-
ressive IP presents with dyspnea, and cough and PFT
esults commonly show a severe restrictive pattern.
neumothorax may occur secondary to severe pulmo-
ary ﬁbrosis. The prognosis is poor because of respi-
atory failure despite augmented immunosuppression.
UMMARY
Both BOS and BOOP are potential “late” pulmo-
ary complications that may occur following allo-
SCT. Importantly, BOS and BOOP each represents
istinct clinical entity, and should not to be used
nterchangeably, although such usage is common. The
disorders are clearly distinct with respect to his-
opathologic ﬁndings, radiographic and functional
haracteristics, and most importantly, response to
herapy. BOOP following allo-HSCT is responsive to
teroids (and in other settings may resolve spontane-
usly), whereas BOS is not. Although diagnostic
ethods and treatment strategies for pulmonary in-
ections have improved signiﬁcantly over the last de-
ade, options in the treatment of noninfectious lung
njury remain limited.
Because the onset and progression of both BOS
nd BOOP can be insidious, pulmonary function test-
ng should be performed every 3 to 4 months for the
rst 2 years posttransplant, particularly in patients
ith cGVHD. A signiﬁcant drop in pulmonary func-
ion should prompt a workup in which careful physical
xamination, radiographic analysis, and BAL are con-
idered. The appropriate use of deﬁned diagnostic
riteria for each condition, in combination with early
iagnosis and well-designed prospective clinical trials,
s required to make progress in outcomes in these
onditions.
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